Skip to main content

CDER

By Dave Muoio | 01:09 pm | June 04, 2019
At BIO 2019 in Philadelphia, a panel of industry experts discussed their experiences with the FDA's pilot program; ambiguities in drug, device and software pathways; and the hurdles digital health regulation has yet to properly address.